These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26122079)

  • 21. Gene therapy for type I glycogen storage diseases.
    Chou JY; Mansfield BC
    Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
    Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
    Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
    Chou JY; Zingone A; Pan CJ
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors.
    Beaty RM; Jackson M; Peterson D; Bird A; Brown T; Benjamin DK; Juopperi T; Kishnani P; Boney A; Chen YT; Koeberl DD
    Gene Ther; 2002 Aug; 9(15):1015-22. PubMed ID: 12101432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancements in AAV-mediated Gene Therapy for Pompe Disease.
    Salabarria SM; Nair J; Clement N; Smith BK; Raben N; Fuller DD; Byrne BJ; Corti M
    J Neuromuscul Dis; 2020; 7(1):15-31. PubMed ID: 31796685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
    Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
    Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice.
    Yiu WH; Pan CJ; Allamarvdasht M; Kim SY; Chou JY
    Gene Ther; 2007 Feb; 14(3):219-26. PubMed ID: 17006547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.
    Yi H; Zhang Q; Brooks ED; Yang C; Thurberg BL; Kishnani PS; Sun B
    Hum Gene Ther; 2017 Mar; 28(3):286-294. PubMed ID: 27832700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
    Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutrition therapy for hepatic glycogen storage diseases.
    Goldberg T; Slonim AE
    J Am Diet Assoc; 1993 Dec; 93(12):1423-30. PubMed ID: 8245377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
    Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction.
    Ding E; Hu H; Hodges BL; Migone F; Serra D; Xu F; Chen YT; Amalfitano A
    Mol Ther; 2002 Apr; 5(4):436-46. PubMed ID: 11945071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.
    Lee YM; Conlon TJ; Specht A; Coleman KE; Brown LM; Estrella AM; Dambska M; Dahlberg KR; Weinstein DA
    J Inherit Metab Dis; 2018 Nov; 41(6):977-984. PubMed ID: 29802554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.
    Rastall DP; Seregin SS; Aldhamen YA; Kaiser LM; Mullins C; Liou A; Ing F; Pereria-Hicks C; Godbehere-Roosa S; Palmer D; Ng P; Amalfitano A
    Gene Ther; 2016 Oct; 23(10):743-752. PubMed ID: 27367841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycogen storage diseases: An update.
    Gümüş E; Özen H
    World J Gastroenterol; 2023 Jul; 29(25):3932-3963. PubMed ID: 37476587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
    Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
    Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glycogenoses--genetic disorders leading to disturbed glycogen metabolism].
    Bejtka M; Malińska D
    Postepy Biochem; 2011; 57(2):148-57. PubMed ID: 21913415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.